Swing Therapeutics announced that Stanza, its digital therapeutic for treatment of fibromyalgia symptoms, has received a positive coverage decision from Highmark Health. Highmark’s commercial members across Pennsylvania, West Virginia, Delaware, and New York now have access to the treatment by prescription, with reimbursement through their insurance.
Stanza, a smartphone-based, self-guided therapy, has demonstrated clinical success in multiple trials, showing improvements in well-being and reductions in fibromyalgia-related symptom activity. Outcomes from the pivotal Phase 3 trial of Stanza were published in The Lancet in July 2024.
This decision marks a significant step forward in increasing access to evidence-based, non-drug treatments for people with fibromyalgia, a widespread chronic pain condition affecting over 4 million Americans.
“Behavioral therapies like Stanza are guideline-directed treatments for fibromyalgia, but until now, access has been limited for both patients and providers,” said Mike Rosenbluth, CEO of Swing. “Highmark’s decision is a pivotal moment for people living with fibromyalgia, offering them the opportunity to incorporate effective, non-drug options into their care plan.”
Stanza is available through Swing Care, a specialty clinic for comprehensive fibromyalgia treatment, which launched in Pennsylvania in 2024. Patients have access to virtual care integrating medication management with non-pharmacological therapies such as behavioral care, sleep management, meaningful movement coaching, and peer support.
“At Swing Care, we’re committed to helping patients find real relief with a supportive, comprehensive approach to managing fibromyalgia that truly improves patients’ lives,” said Dr. Andrea Chadwick, Medical Director of Swing Care. “Incorporating innovative treatments like Stanza is a part of that transformation—and Highmark coverage puts it in reach for many more patients that could benefit.”
For more information on Swing Care and Stanza, visit www.swing.care